The effect of earthworm (Eisenia foetida) meal with vermi-humus on growth performance, hematology, immunity, intestinal microbiota, carcass characteristics, and meat quality of broiler chickens

The present investigation was aimed to evaluate the effect of varied amount of earthworm meal (EW) and vermihumus (VH) on the growth performance of broiler chickens. Three hundred 1-d-old broiler chickens were assigned to 5 starter treatments with 5 pens per treatment, and 12 broiler chickens per pen in a completely randomized design from d 0–14 of the study. Dietary treatments were [per kilogram dry matter (DM)]: control (0 g EW and 0 g VH/kg of DM), and the diets containing 10 g VH/kg of DM supplemented with 0, 10, 20, or 30 g EW/kg of DM. At the end of the study (d 42), one representative broiler chicken per pen, close to the average body weight, was selected for blood sampling using a sterile needle and heparinized vacuum tube. The outcomes of the study depicted the greater overall feed intake value in broiler chicken fed the control diet than those fed the diets containing VH or EW or both, and it decreased linearly and quadratically (P<0.05) as the amount of EW supplementation increased. The average weight gain for the chickens was numerically increased as supplementation of EW was increased (linear, =0.3; quadratic P=0.4). On the other hand, overall feed conversation ratio was slightly greater (P=0.02) in broiler chickens fed the control diet, and it decreased linearly (P=0.03) as dietary EW supplementation increased. Additionally, the serum total protein, albumin, Ca, and P concentrations were lower in broiler chickens fed the control diet, and those variables increased linearly (P<0.05) as dietary EW increased. In like manner, humoral immune response (except heterophil/lymphocyte ratio) and relative weights of immune organs were lower in broiler chickens fed the control diet. Remarkable differences were observed between carcass and ileum characteristics of broiler chickens under treatments. Varied concentrations of EW showed increased total counts of lactic acid bacteria (linear, P<0.05; quadratic, P=0.3) and reduced population of pathogenic intestinal microbiota (linear, P0.05). Similarly, the meat quality of broiler chicken was markedly affected linearly (P<0.05) by the supplementation of increased dietary EW. Briefly, diets containing 30 g EW/kg of DM can positively affect the growth performance of broiler chickens and produce meat with better characteristics

Investigating the effect of light color temperature on selective attention, error and human reaction time

Background and aims: The reaction time of humans that affected by several factors includes the time that takes to stimulate the sensory organs and the stimulus effect is transmitted to the brain, then is perceived and the decision is made; consequently, the command resulting from the decision of the brain is sent from the brain to the functional organs. Failure to respond at the right time may result in human error and accidents. There are important factors that affect the reaction time. Attention is one of the important factors affecting the speed of the reaction. Selective attention and correct perception of several stimuli among the other stimuli is one of the effective factors in promoting performance and safety. Additionally, various environmental factors may be effective in determining selective attention, increasing the number of errors and the human response time in detecting triggers. Lighting is one of the factors affecting the processing mechanisms of the brain. In the design of indoor and outdoor lighting systems, the quality parameters of the lighting system are usually less considered. Color temperature is one of the most important qualitative parameters of light, which is measured by the Kelvin unit and is an indicator for the brightness and color of the light. The aim of this study was to investigate the effect of light color temperature on selective attention, error rate and reaction time. Methods: This research is an interventional and laboratory study in order to determine the effect of the light color temperature on human error, selective attention, and reaction time of students in Tarbiat Modares University (TMU) of Tehran during the fall of 2018. All students were in the same age range. The inclusion criteria for this study were; not having any eye-related diseases, such as diminished vision and subtlety, and mental-psychiatric disorders. On the day before performing the test, participants were informed to: have enough sleep and rest, adhere to a regular diet, and avoid taking medicines, coffee and caffeinated drinks. In this interventional study, 92 students (36 female and 56 male) from Tarbiat Modarres University of Tehran with an average age of 28.33 years were recruited as subjects. The measurements and tests related to selective attention and reaction time of individuals were performed in 4 locations with an equal lighting system and different color temperatures (3500, 4000, 5000, or 6500 degrees Kelvin). In the first step of the study, in order to determine the effect of light color temperature on the studied parameters, the participants were randomly divided into four groups with 24 subjects in each group. Before the main test was being performed, the participants were kept in rooms adjusted to a brightness of 3500° K to rest for at least 5 minutes in order to be adapted to the situation, and then, in the same conditions, to become familiar with the test method they were studied with the Stroop software. In the second step, each group was placed in a separate room where the levels of brightness had been designed with one of the lighting systems to yield a color temperature of 3500, 4000, 5000, and 6500° K. Cognitive performance tests including reaction time, accuracy and selective attention were measured using Stroop tests. Measurement of score interference and time interference, which are indicators for selective attention, were calculated by measuring the difference in the error rate and the reaction time in detecting incongruent and consonant words. Stroop test was used to determine the reaction time, error and other parameters. This test consists of two parts; the practice and the main test, each of them has two stages. The first step is to name the color of circular shapes that appears on the laptop monitor screen. The participant, upon viewing the image, applies pressure on keyboard buttons which are labeled with colors corresponding to the ones on the screen. The second step is to name the word which appears in a white box. The names of the colors appear, and as soon as the correct word is recognized, the participant should press the color word associated to the word on the keyboard. The third step, which is the main stage of the test, is a non-consistent word (red-green-blue) that shown randomly and sequentially on the monitor's screen. The subject must only press the keyboard button with the same color, only emphasizing the color and regardless of its connotation. In this test, 48 consistent colored words (the color of the word is identical with the meaning of the word; red, yellow, green and blue) and 48 non-consistent colored words (the color of the word is not the same as the word meaning; for example, the blue word shown in red). The time lap between the stimulants was 800 milliseconds and the duration of each of them was 2000 milliseconds. The subject's task was to select the correct color only. Finally, the data were analyzed using SPSS software. Results: Based on the results of this study, the highest mean of correct selection (474.49 ± 10.65) and the lowest mean of the correct ones (654.49 ± 11.77) were assigned to the color temperature of 6500 and 3500 ° K, respectively. Also, the highest mean of error rate (15.65 ± 9.77) and the lowest mean of error rate (10.94 ± 9.4) were reported at a color temperature of 3500 and 6500 ° K, respectively. According to the results of this study, with increase in color temperature from 3500 to 5000° Kelvin, the number of questions that were not responded decreased. Likewise, the number of unanswered questions for the color temperature of 6500 °K slightly increased compared to the color temperature of 5000 and 4000 °K. The results also indicated that, with an increase in color temperature from 3500 to 6500 °K, the reaction time to visual stimuli also decreased. The highest interference score was in the light color temperature of 3500 °K which indicates that the number of faults in naming inconsistent words relative to consonant words was higher in color temperature of 3500° K compared to other color temperatures. Also, according to Fig. 3, the maximum interference time was at 6500 ° K. This indicates that the performance time of the subjects in naming inconsistent words was higher relative to consonants in color temperature of 6,500° K compared to other color temperatures. Although the average response time under lighting condition with color temperature of 6500° K (718.95 ± 65.33) was less than the color temperature of 3500° K (728.58 ± 43.48), according to the results of the study, with a decrease in color temperature, the increase in mean response time was observed, but this difference was not significant (p p). Also, based on independent t-test (Table 2), there was a significant relationship between subjects' gender and variables such as interference score, interference time and number of unanswered questions. For all of these three variables (interference score, interference time and number of unanswered questions) mean in men was significantly lower than women (p <0.05). Based on subjects' gender, the average response time under different color temperatures showed that the response time (or reaction time) of female under lighting conditions with 3000 and 5,000 ° K was higher than male, while under lighting conditions with 4000 and 6500° K the response time of male was higher than female students. Although the average response time under different color temperatures was different between male and female subjects, based on the results of independent t-test, such difference was not significant. Conclusion: In general, the results of this study showed that when subjects are exposed to light color temperature of 6,500 ° K, the number of correct responses by them is higher than those exposed to other color temperatures, and with increasing the color temperature, the number of correct answers increases. Also, according to the results of this study, the error rate decrease by increasing color temperature of light source. Based on the results of this study, it is suggested to make use of light sources with a color temperature of 6,500 ° K in designing the lighting system of the places where human reaction time and error are high importance. Accordingly, it is recommended to repeat this study in other demographic groups, as well as taking into account the qualitative parameters of the lighting system in addition to its quantitative parameters. © 2020 Iran University of Medical Sciences. All rights reserved

Synthesis, characterisation and photochemistry of PtIV pyridyl azido acetato complexes

PtII azido complexes [Pt(bpy)(N3)2] (1), [Pt(phen)(N3)2] (2) and trans-[Pt(N3)2(py)2] (3) incorporating the bidentate diimine ligands 2,2′-bipyridine (bpy), 1,10-phenanthroline (phen) or the monodentate pyridine (py) respectively, have been synthesised from their chlorido precursors and characterised by X-ray crystallography; complex 3 shows significant deviation from square-planar geometry (N3–Pt–N3 angle 146.7°) as a result of steric congestion at the Pt centre. The novel PtIV complexes trans, cis-[Pt(bpy)(OAc)2(N3)2] (4), trans, cis-[Pt(phen)(OAc)2(N3)2] (5), trans, trans, trans-[Pt(OAc)2(N3)2(py)2] (6), were obtained from 1–3via oxidation with H2O2 in acetic acid followed by reaction of the intermediate with acetic anhydride. Complexes 4–6 exhibit interesting structural and photochemical properties that were studied by X-ray, NMR and UV-vis spectroscopy and TD-DFT (time-dependent density functional theory). These PtIV complexes exhibit greater absorption at longer wavelengths (ε = 9756 M−1 cm−1 at 315 nm for 4; ε = 796 M−1 cm−1 at 352 nm for 5; ε = 16900 M−1 cm−1 at 307 nm for 6, in aqueous solution) than previously reported PtIV azide complexes, due to the presence of aromatic amines, and 4–6 undergo photoactivation with both UVA (365 nm) and visible green light (514 nm). The UV-vis spectra of complexes 4–6 were calculated using TD-DFT; the nature of the transitions contributing to the UV-vis bands provide insight into the mechanism of production of the observed photoproducts. The UV-vis spectra of 1–3 were also simulated by computational methods and comparison between PtII and PtIV electronic and structural properties allowed further elucidation of the photochemistry of 4–6

Impact damage characteristics of carbon fibre metal laminates : experiments and simulation

In this work, the impact response of carbon fibre metal laminates (FMLs) was experimentally and numerically studied with an improved design of the fibre composite lay-up for optimal mechanical properties and damage resistance. Two different stacking sequences (Carall 3–3/2–0.5 and Carall 5–3/2–0.5) were designed and characterised. Damage at relatively low energy impact energies (≤30 J) was investigated using Ultrasonic C-scanning and X–ray Computed Tomography (X-RCT). A 3D finite element model was developed to simulate the impact induced damage in both metal and composite layers using Abaqus/Explicit. Cohesive zone elements were introduced to capture delamination occurring between carbon fibre/epoxy plies and debonding at the interfaces between aluminium and the composite layers. Carall 5–3/2–0.5 was found to absorb more energy elastically, which indicates better resistance to damage. A good agreement is obtained between the numerically predicted results and experimental measurements in terms of force and absorbed energy during impact where the damage modes such as delamination was well simulated when compared to non-destructive techniques (NDT)

Genetic parameters for growth, reproductive and maternal traits in a multibreed meat sheep population

The genetic parameters for growth, reproductive and maternal traits in a multibreed meat sheep population were estimated by applying the Average Information Restricted Maximum Likelihood method to an animal model. Data from a flock supported by the Programa de Melhoramento Genético de Caprinos e Ovinos de Corte (GENECOC) were used. The traits studied included birth weight (BW), weaning weight (WW), slaughter weight (SW), yearling weight (YW), weight gain from birth to weaning (GBW), weight gain from weaning to slaughter (GWS), weight gain from weaning to yearling (GWY), age at first lambing (AFL), lambing interval (LI), gestation length (GL), lambing date (LD - number of days between the start of breeding season and lambing), litter weight at birth (LWB) and litter weight at weaning (LWW). The direct heritabilities were 0.35, 0.81, 0.65, 0.49, 0.20, 0.15 and 0.39 for BW, WW, SW, YW, GBW, GWS and GWY, respectively, and 0.04, 0.06, 0.10, 0.05, 0.15 and 0.11 for AFL, LI, GL, LD, LWB and LWW, respectively. Positive genetic correlations were observed among body weights. In contrast, there was a negative genetic correlation between GBW and GWS (-0.49) and GBW and GWY (-0.56). Positive genetic correlations were observed between AFL and LI, LI and GL, and LWB and LWW. These results indicate a strong maternal influence in this herd and the presence of sufficient genetic variation to allow mass selection for growth traits. Additive effects were of little importance for reproductive traits, and other strategies are necessary to improve the performance of these animals

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction &gt;0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years